
Opinion|Videos|September 24, 2024
Oral vs. IV HMAs: Considerations and Patient Guidance
Medical experts discuss considerations and patient guidance for oral and IV HMAs.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What considerations can you share regarding switching patients from intravenous to oral therapies during myelodysplastic syndrome treatment, including factors such as efficacy, safety, and patient preferences?
- What are the key differences between oral azacitidine and oral decitabine-cedazuridine in terms of interchangeability and patient management, and how do you navigate these discussions with your patients, particularly if they were receiving intravenous azacitidine initially?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
In Its 50th Year, ESMO Comes to Berlin, a City Transformed
2
Physical Activity, Vaccination May Protect Against Long COVID
3
Real-World Data Show Preventive Nirsevimab Reduces Infant RSV Hospitalizations
4
Medicare State Rankings Reveal Stark Differences in Access, Quality, and Affordability
5